Alternative and Complementary Medicine for Preventing and Treating Cardiovascular Disease

Disease-a-Month

Volumn 55, Issue 3, 2009, Pages 121-192

  Frishman, William H ^a   Beravol, Poojitha ^a   Carosella, Christine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CAROTENOID; CHONDROITIN; CYANOCOBALAMIN; ECHINACEA EXTRACT; FLAVONOID; FOLIC ACID; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLUCOSAMINE; HERBACEOUS AGENT; LYCOPENE; MAGNESIUM; NICOTINAMIDE; NICOTINIC ACID; PLACEBO; POLYPHENOL DERIVATIVE; PROANTHOCYANIDIN DERIVATIVE; PYRIDOXINE; QUERCETIN; RESERPINE; RESVERATROL; THIAMINE; UNINDEXED DRUG; VITAMIN B GROUP; VITAMIN D; VITAMIN K GROUP;

ACANTHOSIS NIGRICANS; ALTERNATIVE MEDICINE; ANGINA PECTORIS; ANTIOXIDANT ACTIVITY; AROMATHERAPY; ASTHMA; ATHEROSCLEROSIS; BEHAVIOR THERAPY; BREATHING EXERCISE; CACAO; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHELATION THERAPY; CHINESE MEDICINE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; DIET SUPPLEMENTATION; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; FEEDBACK SYSTEM; FLUSHING; GASTROINTESTINAL SYMPTOM; GRAPE JUICE; GUIDED IMAGERY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HERBAL MEDICINE; HOMEOPATHY; HUMAN; HUMOR; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; IRON OVERLOAD; LIVER TOXICITY; MAGNESIUM DEFICIENCY; MAGNETOTHERAPY; MEDICAL PRACTICE; MEDITATION; MUSCLE CRAMP; MUSIC THERAPY; NONHUMAN; NONVERBAL COMMUNICATION; OSTEOPATHIC MEDICINE; PATIENT SATISFACTION; PET THERAPY; POLYGALACEAE; PROPHYLAXIS; PRURITUS; RED WINE; REFLEXOLOGY; REVIEW; SAUNA; SIDE EFFECT; SPINAL CORD STIMULATION; STEPHANIA; STROKE; SUSTAINED DRUG RELEASE; TAI CHI; TEA; TRANSCUTANEOUS NERVE STIMULATION; VASODILATATION; VITAMIN SUPPLEMENTATION; YOGA;

CARDIOVASCULAR DISEASES; COMPLEMENTARY THERAPIES; HUMANS; MINERALS; PLANTS, MEDICINAL; TREATMENT OUTCOME; VITAMINS;

EID: 59649084889     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.disamonth.2008.12.002     Document Type: Review

References (337)

1. Eisenberg D.M., Kessler R.C., Foster C., et al. Unconventional medicine in the United States. N Engl J Med 328 (1993) 246-252
2. Pearson N.I., and Chesney M.A. The CAM education program of the National Center for Complementary and Alternative Medicine: an overview. Acad Med 82 (2007) 921-926
3. Gaylord S.A., and Mann J.D. Rationales for CAM education in health professions training programs. Acad Med 82 (2007) 927-933
4. Saydah S.H., and Eberhardt M.S. Use of complementary and alternative medicine among adults with chronic diseases: United States 2002. J Altern Complement Med 12 8 (2006) 805-812
5. Yeh G.Y., Davis R.B., and Phillips R.S. Use of complementary therapies in patients with cardiovascular disease. Am J Cardiol 98 (2006) 673-680
6. Barraco D., Valencia G., Riba A.L., et al. Complementary and alternative medicine (CAM) use patterns and disclosure to physicians in acute coronary syndromes patients. Complement Ther Med 13 1 (2005) 34-40
7. Krasuski R.A., Michaelis K., and Eckart R.E. The cardiovascular patient's perceptions of complementary and alternative medicine. Clin Cardiol 29 (2006) 161-164
8. Honda K., and Jacobson J.S. Use of complementary and alternative medicine among United States adults: the influences of personality, coping strategies, and social support. Prev Med 40 1 (2005) 46-53
9. Krucoff M.W., Liebowitz R., Vogel J.H.K., et al. Complementary and alternative medicine therapy in cardiovascular care. In: Fuster V., Alexander R.W., O'Rourke R.A., et al. (Eds). Hurst's The Heart. 11th ed. (2004), McGraw Hill, New York, NY 2463-2472
10. Frishman W.H., Lee W.-N., Glasser S.P., et al. The placebo effect in cardiovascular disease. In: Frishman W.H., Sonnenblick E.H., and Sica D.A. (Eds). Cardiovascular Pharmacotherapeutics. 2nd ed. (2003), McGraw Hill, New York, NY 15-25
11. Walach H., and Jonas W.B. Placebo research: the evidence base for harnessing self-healing capacities. J Alt Comp Med 10 suppl 1 (2004) 1 S103-12.
12. Matter-Walstra K., Schoeni-Affolter F., Widmer M., et al. Patient-based evaluations of primary care for cardiovascular diseases: a comparison between conventional and complementary medicine. J Eval Clin Pract 14 (2008) 75-82
13. Miller K.L., Liebowitz R.S., and Newby L.K. Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches. Am Heart J 147 (2004) 401-411
14. Morris C.D., and Carson S. Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 139 (2003) 56-70
15. Frishman W.H., Sinatra S.T., and Kruger N. Nutriceuticals and cardiovascular illness. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies for Cardiovascular Disease (2005), Elsevier, St. Louis, MO 58-85
16. Ridinger M.H.T. Nutraceuticals: miracle or meme?. Nature 82 (2007) 352-356
17. Frishman W.H. Nutriceuticals as treatments for cardiovascular disease. (editorial). Heart Dis 1 (1999) 51
18. Riccioni G., Mancini B., Di Ilio E., et al. Protective effect of lycopene in cardiovascular disease. Eur Rev Med Pharmacol Sci 12 (2008) 183-190
19. Frishman W.H., Kruger N.A., Nayak D.U., et al. Antioxidant vitamins and enzymatic and synthetic oxygen-derived free-radical scavengers in the prevention and treatment of cardiovascular disease. In: Frishman W.H., Sonnenblick E.H., and Sica D.A. (Eds). Cardiovascular Pharmacotherapeutics. 2nd ed. (2003), McGraw Hill, New York, NY 407-427
20. Pryor W.A. Vitamin E and heart tissue: basic science to clinical intervention trials. Free Radic Biol Med 28 (2000) 141-164
21. Rapola J.M., Virtamo J., Ripatti S., et al. Randomized trial of alpha-tocopherol and beta carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 349 (1997) 1715-1720
22. Stephens N.G., Parsons A., Schofield P.M., et al. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study. Lancet 347 (1996) 781-786
23. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
24. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI Prevenzione trial. Lancet 354 (1999) 447-455
25. Jialal I., Traber M., and Deveraj S. Is there a vitamin E paradox?. Curr Opin Lipidol 12 (2001) 49-53
26. Vivekananthan D.P., Penn M.S., Sapp S.K., et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomized trials. Lancet 361 (2003) 2017-2023
27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplement in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 23-33
28. Rasool A.H., Rahman A.R., Yuen K.H., et al. Arterial compliance and vitamin E blood levels with a self emulsifying preparation of tocotrienol rich vitamin E. Arch Pharm Res 31 9 (2008) 1212-1217
29. Glynn R.J., Ridker P.M., Goldhaber S.Z., et al. Effects of random allocation of vitamin E supplementation on the occurrence of venous thromboembolism. Report from the Women's Health Study. Circulation 116 (2007) 1497-1503
30. Cook N.R., Albert C.M., Gaziano J.M., et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med 168 7 (2008) 773
31. Sesso H.D., Buring J.E., Christen W.G., et al. Vitamins E and C in the prevention of cardiovascular disease in men. The Physicians' Health Study II randomized controlled trial. JAMA 300 (2008) 2123-2133
32. Hatzigeorgiou C., Taylor A.J., Feuerstein I.M., et al. Antioxidant vitamin intake and subclinical coronary atherosclerosis. Prevent Cardiol 9 (2006) 75-81
33. Kritchevsky S.B., Shimakawa T., Tell G.S., et al. Dietary antioxidants and carotid artery wall thickness: the ARIC Study. Circulation 92 (1995) 2142-2150
34. Osganian S.K., Stampfer M.J., Rimm E., et al. Vitamin C and risk of coronary heart disease in women. J Am Coll Cardiol 42 (2003) 246-252
35. Kaw K.T., Bingham S., Welch A., et al. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk Prospective Study: a prospective population study. Lancet 357 (2001) 657-663
36. Mikirova N.A., Thomas I.E., and Riordan N.H. Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med 6 (2008) 50
37. Kruger N.A., Frishman W.H., and Hussain J. Fish oils, the B vitamins and folic acid as cardiovascular protective agents. In: Frishman W.H., Sonnenblick E.H., and Sica D.A. (Eds). Cardiovascular Pharmacotherapeutics. 2nd ed. (2003), McGraw Hill, New York, NY 381-405
38. Chan P., Huang T.Y., Chen Y.J., et al. Randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension. J Clin Pharmacol 38 (1998) 1151-1154
39. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56 (1969) 111-128
40. Selhub J., Jacques P.F., Bostom A.G., et al. Association between plasma homocysteine concentrations and extracranial carotid artery disease. N Engl J Med 332 (1995) 286-291
41. Ridker P.M., Manson J.E., Buring J.E., et al. Homocysteine and risk of cardiovascular disease among post-menopausal women. JAMA 281 (1999) 1817-1821
42. Hankey G.J., and Eikeboom J.W. Homocysteine and vascular disease. Lancet 354 (1999) 407-413
43. Lonn E. Homocysteine-lowering B vitamin therapy in cardiovascular prevention. Wrong again?. JAMA 299 (2008) 2086-2087
44. Toole J.F., Malinow M.R., Chambless L.E., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291 (2004) 565-575
45. Spence J.D., Bang H., Chambless L.E., et al. Vitamin Intervention for Stroke Prevention trial: an efficacy analysis. Stroke 36 (2005) 2404-2409
46. Ray J.G., Kearon C., Yi Q., et al. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. Ann Intern Med 146 (2007) 761-767
47. Bønaa K.H., Njølstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 (2006) 1578-1588
48. Bleie O., Semb A.G., Grundt H., et al. Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease. J Intern Med 262 (2007) 244-253
49. Albert C.M., Cook N.R., Gaziano J.M., et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 299 (2008) 2027-2036
50. Jamison R.L., Hartigan P., Kaulman J.S., et al., Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease. A randomized controlled trial. JAMA 298 (2007) 1163-1170
51. Kamanna V.S., and Kashyap M.L. Mechanism of action of niacin. Am J Cardiol 101 8A (2008) 20B-26B
52. Meyers C.D., Carr M.C., Park S., et al. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med 139 (2003) 996-1002
53. Morgan J.M., Capuzzi D.M., and Guyton J.R. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 82 (1998) 29U-34U
54. Goldberg A., Alagona Jr. P., Capuzzi D.M., et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 85 (2000) 1100-1105
55. Goldberg A.C. Clinical trial experience with extended-release niacin (Niaspan) dose escalation study. Am J Cardiol 82 (1998) 35U-38U
56. Cefali E.A., Simmons P.D., Stanek E.J., et al. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. Int J Clin Pharmacol Ther 44 12 (2006) 633-640
57. Paolini J.F., Mitchel Y.B., Reyes R., et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 101 5 (2008) 625-630
58. Lai E., Lepeleire I., Crumley T.M., et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Therap 81 (2007) 849-857
59. Somjen D., Weisman Y., Kohen F., et al. 25-Hydroxyvitamin D3-1α-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 111 (2005) 1666-1671
60. Merke J., Milde P., Lewicka S., et al. Identification and regulation of 1,25-hydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3: studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 83 (1989) 1903-1915
61. Holick M.F. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81 (2006) 353-373
62. Moats C., and Rimm E.B. Vitamin intake and risk of coronary disease: observation versus intervention. Curr Atheroscler Rep 9 (2007) 508-514
63. Wallis D.E., Penckofer S., and Sizemore G.W. The "Sunshine Deficit" and cardiovascular disease. Circulation 118 (2008) 1476-1485
64. Dobnig H., Pilz S., Scharnagl H., et al. Independent association of low serum 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 168 (2008) 1340-1349
65. Giovannucci E., Liu Y., Hollis B.W., et al. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 168 (2008) 1174-1180
66. Resnick L.M., Muller F.B., and Laragh J.H. Calcium-regulating hormones in essential hypertension: relation to plasma renin activity and sodium metabolism. Ann Intern Med 105 (1986) 649-654
67. Zittermann A., Schleithoff S.S., and Koerfer R. Vitamin D and vascular calcification. Curr Opin Lipidol 18 (2007) 41-46
68. Wang T.J., Pencina M.J., Booth S.L., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 117 (2008) 503-511
69. Pilz S., Dobnig H., Fischer J.E., et al. Low vitamin D levels predict stroke in patients referred to coronary angiography. Stroke 39 (2008) 2611-2613
70. Pilz S., Marz W., Wellnitz B., et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 93 (2008) 3927-3935
71. Fleck A. Latitude and ischaemic heart disease. Lancet 1 (1989) 613
72. Zittermann A., and Koerfer R. Vitamin D in the prevention and treatment of coronary heart disease. Curr Opin Clin Nutr Metab Care 11 (2008) 752-757
73. Erkkila A.T., and Booth S.L. Vitamin K intake and atherosclerosis. Curr Opin Lipidol 19 (2008) 39-42
74. Greenberg E.R., Baron J.A., Karagas M.R., et al. Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation. JAMA 275 (1996) 699-703
75. Gey F.K., and Puska P. Plasma vitamin E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology. Ann NY Acad Sci 570 (1989) 268-282
76. Kardinaal A.F., Kok F.J., Ringstad J., et al. Antioxidants in adipose tissue and risk of myocardial infarction: the EURAMIC Study. Lancet 342 (1993) 1379-1384
77. Gitenay D., Lyan B., Rambeau M., et al. Comparison of lycopene and tomato effects on biomarkers of oxidative stress in vitamin E deficient rats. Eur J Nat 46 8 (2008) 468-475
78. Ullah M.F., and Khan M.W. Food as medicine: potential therapeutic tendencies of plant derived polyphenolic compounds. Asian Pac J Cancer Prev 9 2 (2008) 187-196
79. Maxwell S., Cruickshank A., and Thorpe D. Red wind and antioxidant activity in serum. Lancet 344 (1994) 193-194
80. Hertog M.C., Feskens E.J., Hollman P.C., et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342 (1993) 1007-1011
81. Duffy S.J., Keaney J.F., Holbrook M., et al. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 104 (2001) 151-156
82. Gresele P., Pignatelli P., Guglielmini G., et al. Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J Nutr 138 9 (2008) 1602-1608
83. Clinical Trial: Trial to assess bioavailability of flavonoids and phenolic acids. www.clinicaltrials.gov/ct
84. Rimm E.B., Katan M.B., Ascherio A., et al. Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Ann Intern Med 125 (1996) 384-389
85. Clinical Trial: Trial to assess concord grape juice. www.clinicaltrials.gov/ct
86. Frishman W.H., DelVecchio A., Sanal S., et al. Cardiovascular manifestations of substance abuse. Part 2: Alcohol, amphetamines, heroin, cannabis, caffeine. Heart Dis 5 (2003) 253-271
87. Mehrinfar R., and Frishman W.H. Flavanol-rich cocoa. A cardioprotective nutriceutical. Cardiol Rev 16 (2008) 109-115
88. Hollenberg N.K., and Fisher N.D.L. Is it the dark in dark chocolate?. Circulation 116 (2007) 2360-2362
89. Cohen D.L., and Townsend R.R. Cocoa ingestion and hypertension-another cup please?. J Clin Hypertens 9 (2007) 647-648
90. Flammer A.J., Hermann F., Sudano I., et al. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation 116 (2007) 2376-2382
91. Houston M.C., and Harper K.J. Potassium, magnesium, and calcium: their role in both the cause and treatment of hypertension. J Clin Hypertens (Greenwich) 10 7 suppl 2 (2008) 3-11
92. Cojocaru I.M., Cojocaru M., Burcin C., et al. Serum magnesium in patients with acute ischemic stroke. Rom J Intern Med 45 3 (2008) 269-273
93. McLean R.M. Magnesium and its therapeutic uses: a review. Am J Med 96 (1994) 63-76
94. Shechter M. Oral magnesium in coronary artery disease: fresh insight on thrombus inhibition. Magn Rep (1999) 1-4
95. Ho K.M. Intravenous magnesium for cardiac arrhythmias: jack of all trades. Magnes Res 21 1 (2008) 65-68
96. Shechter M., Merz C.N., Paul-Labrador M., et al. Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am J Cardiol 84 (1999) 152-156
97. Lichodziejewska B., Klos J., Rezler J., et al. Clinical symptoms of mitral valve prolapse are related to hypomagnesemia and attenuated by magnesium supplementation. Am J Cardiol 79 (1997) 768-772
98. Preuss H.G., Wallerstedr' D., Talpur N., et al. Effects of niacin-bound chromium and grape seed proanthocyanidins extract on the lipid profile of hypercholesterolemic subjects: a pilot study. J Med 31 5 and 6 (2000) 227-246
99. Grundy S.M. Cholesterol management in the era of managed care. Am J Cardiol 85 (2000) 3A-9A
100. McLaren D.S. Vitamin deficiency, toxicity and dependency. In: Berkow R., Fletcher A.J., Bondy P.K., et al. (Eds). The Merck Manual. 16th ed. (1992), Merck Research Labs, Rahway, NJ
101. Salvini S., Hennekens C.H., Morris J.S., et al. Plasma levels of the antioxidant selenium and risk of myocardial infarction among US physicians. Am J Cardiol 76 (1995) 1218-1221
102. Kok F.J., Hofman A., Witteman J.C.M., et al. Decreased selenium levels in acute myocardial infarction. JAMA 261 (1989) 1161-1164
103. Hercberg S., Galan P., Preziosi P., et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 164 21 (2004) 2335-2342
104. Kendler B.S. Recent nutritional approaches to the prevention and therapy of cardiovascular disease. Prog Cardiovasc Nurs 12 (1997) 3-23
105. Salonen J.T., Salonen R., Seppanen K., et al. Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis. BMJ 302 (1991) 756-760
106. Kuklinski B., Weissenbacher E., Fahnrich A., et al. Coenzyme Q10 and antioxidants in acute myocardial infarction. Mol Aspects Med 15 (1994) S143-S147
107. Molyneux S.L., Young J.M., Florkowski C.M., et al. Coenzyme q10: is there a clinical role and a case for measurement?. Clin Biochem Rev 29 2 (2008) 71-82
108. Langsjoen P.H., and Langsjoen A.M. Overview of the use of CoQ10 in cardiovascular disease. Biofactors 9 (1999) 273-284
109. Miguel-Carrasco J.L., Mate A., Monserrat M.T., et al. The role of inflammatory markers in the cardioprotective effect of L-carnitine in L-NAME-induced hypertension. Am J Hypertens (2008) September 11,(epub ahead of print).
110. Wierzbicki A.S. A fishy business: omega-3 fatty acids and cardiovascular disease. Int J Clin Pract 62 8 (2008) 1142-1146
111. Brouwer I.A., Zock P.L., Camm A.J., et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 295 22 (2006) 2613-2619
112. Kenny D., Warltier D.C., Pleuss J.A., et al. Effect of omega-3 fatty acids on the vascular response to angiotensin in normotensive men. Am J Cardiol 70 (1992) 1347-1352
113. Kestin M., Clifton P., Belling G.B., et al. N-3 fatty acids of marine origin lower systolic blood pressure and triglycerides but raise LDL cholesterol compared with n-3 and n-6 fatty acids from plants. Am J Clin Nutr 51 (1990) 1028-1034
114. O'Keefe J., and Harris W. Omega-3 fatty acids: time for clinical implementation?. Am J Cardiol 85 (2000) 1239-1241
115. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 1223-1230
116. Fonarow G.C. Statins and n-3 fatty acid supplementation in heart failure. Lancet 372 (2008) 1195-1196
117. Albert C.M., Hennekens C.H., O'Donnell C.J., et al. Fish consumption and risk of sudden cardiac death. JAMA 279 (1998) 23-28
118. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369 9597 (2007) 1090-1098
119. Rauch B., Schiele R., Schneider S., et al. Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction-aims and methods of the OMEGA-study. Cardiovasc Drugs Ther 20 5 (2006) 365-375
120. Siani A., Pagano E., Iacone R., et al. Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. Am J Hypertens 13 (2000) 547-551
121. Candipan R.C., Wang B., Buitrago R., et al. Regression or progression. Dependency on vascular nitric oxide. Arteriothromb Vasc Biol 16 (1996) 44-50
122. Drexler H., Zeiher A.M., Meinzer K., et al. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine. Lancet 338 (1991) 1546-1550
123. Egashira K., Hirooka Y., Kuga T., et al. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary angiograms. Circulation 94 (1996) 130-134
124. Quyyumi A., Dakak N., Diodati J., et al. Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. J Am Coll Cardiol 30 (1997) 1220-1227
125. Lerman A., Burnett Jr. J.C., Higano S.T., et al. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 97 (1998) 2123-2128
126. Blum A., Hathaway L., Mincemoyer R., et al. Oral L-arginine in patients with coronary artery disease on medical management. Circulation 101 (2000) 2160-2164
127. Loscalzo J., and Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 38 (1995) 87-104
128. Quyyumi A. Does acute improvement of endothelial dysfunction in coronary artery disease improve myocardial ischemia?. A double-blind comparison of parenteral D- and L-arginine. J Am Coll Cardiol 32 (1998) 904-911
129. Ito T., Kimura Y., Uozumi Y., et al. Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. J Mol Cell Cardiol 44 5 (2008) 927-937
130. Oudit G.Y., Trivieri M.G., Khaper N., et al. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload marine model. Circulation 109 (2004) 1877-1885
131. Safi A.M., and Stein R.A. Role of nutriceutical agents in cardiovascular diseases: an update-Part I. Cardiovasc Rev Rep 24 (2003) 382-385
132. Solerte S.B., Fioravanti M., Locatelli E., et al. Improvement of blood glucose control and insulin sensitivity during a long-term (60 weeks) randomized study with amino acid dietary supplements in elderly subjects with type 2 diabetes mellitus. Am J Cardiol 101 suppl 11A (2008) 82E-88E
133. Kalantar-Zadeh K., Anker S.D., Horwich T.B., et al. Nutritional and anti-inflammatory interventions in chronic heart failure. Am J Cardiol 101 suppl 11A (2008) 89E-103E
134. Aquilani R., Viglio S., Iadarola P., et al. Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure. Am J Cardiol 101 suppl 11A (2008) 104E-110E
135. Corsetti G., Pasini E., D'Antona G., et al. Morphometric changes induced by amino acid supplementation in skeletal and cardiac muscles of old mice. Am J Cardiol 101 suppl 11A (2008) 26E-34E
136. Scarabelli T.M., Townsend P.A., Scarabelli C.C., et al. Amino acid supplementation differentially modulates STAT1 and STAT3 activation in the myocardium exposed to ischemia/reperfusion injury. Am J Cardiol 101 suppl 11A (2008) 63E-68E
137. Scarabelli T.M., Pasini E., Stephanou A., et al. Nutritional supplementation with mixed essential amino acids enhances myocycte survival, preserving mitochondrial functional capacity during ischemia-reperfusion injury. Am J Cardiol 93 8A (2004) 35A-40A
138. Frishman W.H., Sinatra S.T., and Moizuddin M. The use of herbs for treating cardiovascular disease. Sem Integr Med 2 (2004) 23-35
139. Sinatra S.T., Frishman W.H., and Peterson S.J. Use of alternative medicines in treating cardiovascular disease. In: Frishman W.H., Sonnenblick E.H., and Sica D.A. (Eds). Cardiovascular Pharmacotherapeutics Manual. 2nd ed. (2004), McGraw Hill, New York, NY 485-512
140. Frishman W.H., Sinatra S.T., and Moizuddin M. Herbal approach to cardiac disease. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies for Cardiovascular Disease (2005), Elsevier, St. Louis, MO 86-106
141. Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med 135 (2001) 594-600
142. Sinatra S.T., Frishman W.H., Peterson S.J., et al. Use of alternative/complementary medicine in treating cardiovascular disease. In: Frishman W.H., Sonnenblick E.H., and Sica D.A. (Eds). Cardiovascular Pharmacotherapeutics. 2nd ed. (2003), McGraw Hill, New York, NY 857-874
143. Marcus D.M., and Grollman A.P. Botanical medicine-the need for new regulations (sounding board). N Engl J Med 347 (2002) 2073-2076
144. Slifman N.R., Obermeyer W.R., Musser S.M., et al. Contamination of botanical dietary supplements by Digitalis lanata. N Engl J Med 339 (1998) 806-811
145. Radford D.J., Gillies A.D., Hinds J.A., et al. Naturally occurring cardiac glycosides. Med J Aust 144 (1986) 540
146. Dasgupta A., Tso G., and Wells A. Effect of Asian ginseng, Siberian ginseng, and Indian ayurvedic medicine Ashwagandha on serum digoxin measurement by Digoxin III, a new digoxin immunoassay. J Clin Lab Anal 22 4 (2008) 295-301
147. Clinical Trial: Trial to assess safety of hawthorn and digoxin in CHF. www.clinicaltrials.gov/ct
148. Clinical Trial: Trial to assess effect of hawthorn in CHF. www.clinicaltrials.gov/ct
149. Aaronson K. HERB CHF (Hawthorn Extract Randomized Blinded Chronic HF Study) presented at the 8th Annual Scientific Meeting of the Heart Failure Society of America (2004) September 12-15, Toronto, Canada.
150. Zick S.M., Gillespie B., and Aaronson K.D. The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. Eur J Heart Fail 10 6 (2008) 587-593
151. Jerie P. Milestones of cardiovascular therapy. IV. Reserpine. Cas Lek Cesk 146 7 (2007) 573-577
152. Sutter M.C., and Wang Y.X. Recent cardiovascular drugs from Chinese medicinal plants. Cardiovasc Res 27 (1993) 1891-1901
153. Kawashima K., Hayakawa T., Miwa Y., et al. Structure and hypotensive activity relationships of tetrandrine derivatives in stroke-prone spontaneously hypertensive rats. Gen Pharmacol 21 (1990) 343-347
154. Ody P. The Complete Medicinal Herbal (1993), Dorling Kindersley, New York, NY
155. Ma G., Ding S., Feng Y., et al. Tetramethylpyrazine-eluting stents prevented in-stent restenosis in a porcine model. J Cardiovasc Pharmacol 50 2 (2007) 201-205
156. Kuramochi T., Chu J., and Suga T. Gou-teng (from Uncaria rhynchophylla Miquel) induced endothelium-dependent and independent relaxations in the isolated rat aorta. Life Sci 54 (1994) 2061-2069
157. Wang L., Li W., and Liu Y. Hypotensive effect and toxicology of total alkaloids and veratramine from roots and rhizomes of Veratrum nigrum L. in spontaneously hypertensive rats. Pharmazie 63 8 (2008) 606-610
158. Chang Q., Zuo Z., Harrison F., et al. Hawthorn. J Clin Pharmacol 42 (2002) 605-612
159. Vibes J., Lasserre B., Gleye J., et al. Inhibition of thromboxane A2 biosynthesis in vitro by the main components of Crataegus oxyacantha (hawthorn) flower heads. Prostaglandins Leukot Essent Fatty Acids 50 (1994) 173-175
160. Shanthi S., Parasakthy K., Deepalakshmi P.D., et al. Hypolipidemic activity of tincture of Crataegus in rats. Indian J Biochem Biophys 31 (1994) 143-146
161. Nasa Y., Hashizume H., Hoque A.N., et al. Protective effect of Crataegus extract on the cardiac mechanical dysfunction in isolated perfused working rat heart. Arzneimittelforschung 43 (1993) 945-949
162. Roddewig C., and Hensel H. Reaction of local myocardial blood flow in non-anesthetized dogs and anesthetized cats to the oral and parenteral administration of a Crataegus fraction (oligomere procyanidines). [German]. Arzneimittelforschung 27 (1977) 1407-1410
163. Baughman K.L., and Bradley D.J. Hawthorn extract: is it time to turn over a new leaf?. Am J Med 114 (2003) 700-701
164. Pittler M.H., Schmidt K., and Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. Am J Med 114 (2003) 665-674
165. Schussler M., Holzl J., and Fricke U. Myocardial effects of flavonoids from Crataegus species. Arzneim Forsch 45 (1995) 842-845
166. Zhang W., Wojta J., and Binder B.R. Effect of notoginsenoside R1 on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Arterioscler Thromb 14 (1994) 1040-1046
167. Lin S.G., Zheng X.L., Chen Q.Y., et al. Effect of Panax notoginseng saponins on increased proliferation of cultured aortic smooth muscle cells stimulated by hypercholesterolemic serum. Chung Kuo Yao Li Hsueh Pao 14 (1993) 314-316
168. Zhang Y.G., Zhang H.G., Zhang G.Y., et al. Panax Notoginseng saponins attenuate atherosclerosis in rats by regulating the blood lipid profile and an anti-inflammatory action. Clin Exp Pharmacol Physiol (2008) July 9, (epub ahead of print).
169. Lam F.F., Yeung J.H., Chan K.M., et al. Dihydrotanshinone, a lipophilic component of Salvia Miltiorrhiza (danshen), relaxes rat coronary artery by inhibition of calcium channels. J Ethnopharmacol 119 2 (2008) 318-321
170. Ried K., Frank O.R., Stocks N.P., et al. Effect of garlic on blood pressure: a systematic review and meta-analysis. BMC Cardiovascular Disord 8 (2008) 13
171. Lau B.H. Suppression of LDL oxidation by garlic compounds is a possible mechanism of cardiovascular health benefit. J Nutr 136 3 (2006) 765S-768S
172. Gardner C.D., Lawson L.D., Block E., et al. Effect of raw garlic vs commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: a randomized clinical trial. Arch Intern Med 167 4 (2007) 325-326
173. Ackermann R.T., Mulrow C.D., Ramirez G., et al. Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med 161 (2001) 813-824
174. Silagy C.A., and Neil H.A. A meta-analysis of the effect of garlic on blood pressure. J Hypertens 12 (1994) 463-468
175. Silagy C., and Neil A. Garlic as a lipid lowering agent-a meta-analysis. J R Coll Physicians Lond 28 (1994) 39-45
176. Clinical Trial: Trial to identify the anti-blood-clotting compounds in garlic. www.clinicaltrials.gov/ct
177. Tyler V.E. Herbs of choice. In: Tyler V.E. (Ed). The Therapeutic Use of Phytomedicinals (1994), Pharmaceutical Product Press, New York, NY
178. Kong W.J., Wei J., Zuo Z.Y., et al. Combination of simvastatin with berberine improves thelipid-lowering efficacy. Metabolism 57 8 (2008) 1029-1037
179. Low Dog T. Herbs in cardiovascular diseases. Botanical Medicine in Modern Clinical Practice 8th Annual Course (2003), Columbia University, New York June 9-13
180. Saper R.B., Phillips R.S., Sehgal A., et al. Lead, mercury and arsenic in US- and Indian-manufactured ayurvedic medicines sold via the internet. JAMA 300 (2008) 915-923
181. Clinical Trials. Safety of an herbal treatment for high cholesterol in individuals with statin intolerance. www.clinicaltrials.gov/ct
182. Clinical Trials. Statin therapy vs. therapeutic lifestyle changes and supplements. www.clinicaltrials.gov/ct
183. Gardner C.D., Taylor-Piliae R.E., Kiazand A., et al. Effect of Ginkgo biloba (EGb 761) on treadmill walking time among adults with peripheral artery disease: a randomized clinical trial. J Cardiopulm Rehabil Prev 28 4 (2008) 258-265
184. Stevermer J.J., and Lindbloom E.J. Ginkgo biloba for dementia. J Fam Pract 46 (1998) 20
185. Solomon P.R., Adams F., Silver A., et al. Ginkgo for memory enhancement. A randomized controlled trial. JAMA 288 (2002) 835-840
186. Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet 352 (1998) 36
187. Matthews M.K. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 50 (1998) 1933-1934
188. Rowin J., and Lewis S.L. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 46 (1996) 1775-1776
189. Gianni L., and Dreitlein W.B. Some popular OTC herbals can interact with anticoagulant therapy. US Pharm 23 (1998) 80
190. Offord E.A., Mace K., Ruffieux C., et al. Rosemary components inhibit benzo(a)pyrene-induced genotoxicity in human bronchial cells. Carcinogenesis 16 (1995) 2057-2062
191. Haraguchi H., Saito T., Okamura N., et al. Inhibition of lipid peroxidation and superoxide generation by diterpenoids from Rosmarinus officinalis. Planta Med 61 (1995) 333-336
192. Larrondo J.V., Agut M., and Calvo-Torras M.A. Antimicrobial activity of essences from labiates. Microbios 82 (1995) 171-172
193. al-Hader A.A., Hasan Z.A., and Aqel M.B. Hyperglycemic and insulin release inhibiting effects of Rosmarinus officinalis. J Ethnopharmacol 43 (1994) 217-221
194. Tyler V.E. The Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. 3rd ed. (1993), Pharmaceutical Product Press, New York, NY
195. Diehm C., Vollbrecht D., Amendt K., et al. Medical edema protection-clinical benefit in patients with chronic deep vein incompetence: a placebo controlled double blind study. Vasa 21 (1992) 188-192
196. Lang W. Studies on the percutaneous absorption of 3H-aescin in pigs. Res Exp Med 169 (1977) 175-187
197. Berg D. Venous constriction by local administration of ruscus extract. (German). Fortschr Med 108 (1990) 473-476
198. Berg D. Venous tonicity in pregnancy varicose veins. (German). Fortschr Med 110 67 (1992) 71
199. Li Y.P., and Wang Y.M. Evaluation of tussilagone: a cardiovascular respiratory stimulant isolated from Chinese herbal medicine. Gen Pharmacol 19 (1988) 261-263
200. Flanagan C.M., Kaesberg J.L., Mitchell E.S., et al. Coronary artery aneurysm and thrombosisfollowing chronic ephedra use. Int J Cardiol (2008) August 19, (epub ahead of print).
201. Chan T.Y.K., Chan J.C.N., Tomlinson B., et al. Chinese herbal medicines revisited: the Hong Kong perspective. Lancet 342 (1993) 1532-1534
202. Horowitz R.S., Feldhaus K., Dart R.C., et al. The clinical spectrum of Jin Bu Huan toxicity. Arch Intern Med 156 (1996) 899-903
203. Frishman W.H., Opie L.H., and Sica D.A. Adverse cardiovascular drug interactions and complications. In: Fuster V., Alexander R.W., O'Rourke R.A., et al. (Eds). Hurst's The Heart. 11th ed. (2004), McGraw Hill, New York, NY 2169-2188
204. Wang Z., Gorski C., Hamman M.A., et al. The effects of St. John's Wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70 (2001) 317-326
205. Tannergran C., Engman H., Knutson L., et al. St. John's wort decreases the bioavailability of R- and S-verapamil through induction of first-pass metabolism. Clin Pharmacol Ther 75 (2004) 298-309
206. Mueller S.C., Uehleke B., Woehling H., et al. Effect of St. John's wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 75 (2004) 546-557
207. Ernst E. The risk-benefit profile of commonly used herbal therapies: ginkgo, St. John's wort, ginseng, Echinacea, saw palmetto and kava. Ann Intern Med 136 (2002) 42-53
208. Yuan C.-S., Wei G., Dey L., et al. Brief communications: American ginseng reduces warfarin's effect in healthy patients. Ann Intern Med 141 (2004) 23-27
209. Clauson K.A., Santamarina M.L., and Rutledge J.C. Clinically relevant safety issues associated with St. John's wort product labels. BMC Complement Altern Med 8 (2008) 42
210. Grattan J.G. Mind-body approach to cardiac illness. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies in Cardiovascular Disease (2005), Elsevier, St. Louis, MO 108-126
211. Reibel D.K., Greeson J.M., Brainard G.C., et al. Mindfulness-based stress reduction and health-related quality of life in a heterogeneous patient population. Gen Hosp Psychiatry 23 (2001) 183-192
212. Teasdale J.D., Segal Z.V., Williams J.M., et al. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 68 (2000) 615-623
213. Paul-Labrador M., Polk D., Dwyer J.H., et al. Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease. Arch Intern Med 166 (2006) 1218-1224
214. Schneider R.H., Nidich S.I., Salerno J.W., et al. Lower lipid peroxide levels in practitioners of transcendental meditation program. Psychosom Med 60 (1998) 38-41
215. Anderson J.W., Liu C., and Kryscio R.J. Blood pressure response to transcendental meditation: a meta-analysis. Am J Hypertens 21 (2008) 310-316
216. Cunningham C., Brown S., and Kaski J.C. Effects of transcendental meditation on symptoms and electrocardiographic changes in patients with cardiac syndrome. Am J Cardiol 85 (2000) 653-655
217. Patel D., Marmot M.G., Terry D.J., et al. Trial of relaxation in reducing coronary risk: four year follow up. Br Med J (Clin Res Ed) 290 (1985) 1103-1106
218. Clinical Trials. Effects of meditation on mechanism of coronary heart disease. www.clinicaltrials.gov/ct
219. Clinical Trials. Mindfulness based stress reduction for high blood pressure. www.clinicaltrials.gov/ct
220. Clinical Trials. Improvement in clinical outcomes in heart failure patients with ICDs that practice meditation. www.clinicaltrials.gov/ct
221. Harmon R.L., and Myers M.A. Prayer and meditation as medical therapies. Phys Med Rehabil Clin North Am 10 (1999) 651-662
222. Al A., Dunkle R.E., Peterson C., et al. The role of private prayer in psychological recovery among midlife and aged patients following cardiac surgery. Gerontologist 38 (1998) 591-601
223. Harris W.S., Gowda M., Kolb J.W., et al. A randomized controlled trial of the effects of remote, intercessory prayer on outcomes in patients admitted to the coronary care unit. Arch Intern Med 159 (1999) 2273-2278
224. Aviles J.M., Wheelan S.E., Hernke D.A., et al. Intercessory prayer and cardiovascular disease progression in a coronary care unit population: a randomized controlled trial. Mayo Clin Proc 76 (2001) 1192-1198
225. Krucoff M.W., Crater S.W., Green C.L., et al. Integrative noetic therapies as adjuncts to percutaneous intervention during unstable coronary syndromes: monitoring and actualization of noetic training (MANTRA) feasibility pilot. Am Heart J 142 (2001) 760-767
226. Krucoff M.W., Crater S.W., Gallup D., et al. Music, imagery, touch, and prayer as adjuncts to interventional cardiac care: the Monitoring and Actualisation of Noetic Trainings (MANTRA) II randomised study. Lancet 366 (2005) 211-217
227. Trakhtenberg E.C. The effects of guided imagery on the immune system: a critical review. Int J Neurosci 118 6 (2008) 839-855
228. Richardson M.A., Post-White J., Grimm E.A., et al. Coping, life attitudes and immune responses to imagery and group support after breast cancer treatment. Altern Ther Health Med 3 (1997) 62-70
229. Spiegel D., and Moore R. Imagery and hypnosis in the treatment of cancer patients. Oncology 11 (1997) 1179-1189
230. Fass A.E. Hypnosis for the relief of cardiac symptomatology. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies for Cardiovascular Disease (2005), Elsevier, St. Louis, MO 127-134
231. Benson H., Frankel F.H., Apel R., et al. Treatment of anxiety: a comparison of the usefulness of self-hypnosis and a meditational relaxation technique. An overview. Psychother Psychosom 30 (1978) 229-242
232. DeBenedittis G., Cigada M., Bianchi A., et al. Autonomic changes during hypnosis: a heart rate variability power spectrum analysis as a marker of sympatho-vagal balance. Int J Clin Exp Hypn 42 (1994) 140-152
233. Das S., and O'Keefe J.H. Behavioral cardiology: recognizing and addressing the profound impact of psychosocial stress on cardiovascular health. Curr Hypertens Rep 10 5 (2008) 374-381
234. Blumenthal J.A., Babyak M., Wei J., et al. Usefulness of psychosocial treatment of mental stress-induced myocardial ischemia in men. Am J Cardiol 89 (2002) 164-168
235. Blumenthal J.A., Jiang W., Babyak M.A., et al. Stress management and exercise training in cardiac patients with myocardial ischemia. Arch Int Med 157 (1997) 2213-2223
236. Burker E.J., Fredrikson M., Rifai N., et al. Serum lipids, neuroendocrine, and cardiovascular responses to stress in men and women with mild hypertension. BehavMed 19 (1994) 155-161
237. Schneider R.H., Staggers F., Alexander C.N., et al. A randomized controlled trial of stress reduction for hypertension in older African Americans. Hypertension 26 (1995) 820-827
238. McGrady A. Biofeedback in cardiovascular disease. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies for Cardiovascular Disease (2005), Elsevier, St. Louis, MO 135-150
239. Schwartz M., and Andrasik F. Biofeedback. A Practitioner's Guide. 3rd ed. (2003), Guilford Press, New York, NY
240. In: Lehrer P., and Woolfolk R.L. (Eds). Principles and Practice of Stress Management. 2nd ed. (1993), Guilford Press, New York, NY
241. Clinical Trials. Hypertension: Prediction of biofeedback success. www.clinicaltrials.gov/ct
242. Clinical Trials. Impact of a psychological biofeedback-relaxation intervention on clinical, physical and psychological outcomes in patients with heart failure. www.clinicaltrials.gov/ct
243. Bruscia K.E. Defining Music Therapy (1998), Barcelona, Gilsum, Pa 20
244. Hanser S.B., and Mandel S.E. The effects of music therapy in cardiac healthcare. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies in Cardiovascular Disease (2005), Elsevier, St. Louis, MO 320-330
245. Logtenberg S.J., Kleefstra N., Houweling S.T., et al. Effect of device-guided breathing exercises on blood pressure in hypertensive patients with type 2 diabetes mellitus: a randomized controlled trial. J Hypertens 25 (2007) 241-246
246. Hirsch A.R. Aromatherapy in cardiac conditions. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies in Cardiovascular Disease (2005), Elsevier, St. Louis, MO 300-319
247. Stein T.R., and Oz M. Integrative medicine in cardiothoracic surgery. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies in Cardiovascular Disease (2005), Elsevier, St. Louis, MO 398-414
248. Sahakian A., and Frishman W.H. Humor and the cardiovascular system. Altern Therap 13 (2007) 56-58
249. Fry W.F. The physiologic effects of humor, mirth and laughter. JAMA 267 (1992) 1857-1858
250. Black D.W. Laughter. JAMA 252 (1984) 2995-2998
251. Berk L.S., Tan S.A., Fry W.F., et al. Neuroendocrine and stress hormone changes during mirthful laughter. Am J Med Sci 298 (1989) 390-396
252. LaForge R. Mind-body fitness: encouraging prospects for primary and secondary prevention. J Cardiovasc Nurs 11 (1997) 53-65
253. Raju P.S., Prasad K.V., Venkata R.Y., et al. Influence of intensive yoga training on physiological changes in 6 adult women: a case report. J Altern Complement Med 3 (1997) 291-295
254. Cohen D., and Townsend R.R. Yoga and hypertension. J Clin Hypertens 9 (2007) 800-801
255. Ornish D., Scherwitz L.W., Billings J.H., et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 280 (1998) 2001-2007
256. Manchanda S.C., Narang R., Reddy K.S., et al. Retardation of coronary atherosclerosis with yoga lifestyle intervention. J Assoc Physicians India 48 (2000) 687-694
257. Clinical Trials. The Penn Lifestyle Modification and Blood Pressure Study. www.clinicaltrials.gov/ct
258. Jahnke R. Qigong and tai chi: traditional Chinese health promotion practices in the prevention and treatment of cardiovascular disease. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies for Cardiovascular Disease (2005), Elsevier, St. Louis, MO 204-219
259. Lan C., Chen S.Y., Wong M.K., et al. Tai Chi training for patients with coronary heart disease. Med Sport Sci 52 (2008) 182-194
260. Channer K.S., Barrow D., Barrow R., et al. Changes in haemodynamic parameters following Tai Chi Chuan and aerobic exercise in patients recovering from acute myocardial infarction. Postgrad Med J 72 (1996) 349-351
261. Tsai J.C., Wang W.H., Chan P., et al. The beneficial effects of Tai Chi Chuan on blood pressure and lipid profile and anxiety status in a randomized controlled trial. J Altern Complement Med 9 (2003) 747-754
262. Lan C., Su T.C., Chen S.Y., et al. Effect of Tai Chi Chuan training on cardiovascular risk factors in dyslipidemic patients. J Altern Complement Med 14 (2008) 813-819
263. Taylor-Piliae R.E. Tai Chi as an adjunct to cardiac rehabilitation exercise training. J Cardiopulm Rehabil 23 (2003) 90-96
264. Lan C., Chan S.Y., and Wong M.K. The effect of Tai Chi on cardiorespiratory function in patients with coronary artery bypass surgery. Med Sci Sports Exerc 31 (1999) 634-638
265. Yeh G.Y., Wood M.J., Lorell B.H., et al. Effects of tai chi mind-body movement therapy on functional status and exercise capacity in patients with chronic heart failure: a randomized controlled trial. Am J Med 117 (2004) 541-548
266. Prasher B., Negi S., Aggarwal S., et al. Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda. J Transl Med 6 1 (2008) 48
267. Gerson S. Ayurveda: The Ancient Indian Healing Art. 1st ed. (1993), Elements Books Limited, Boston, MA (Reprinted 1998).
268. Mamtani R., and Mamtani R. Ayurveda and yoga in cardiovascular diseases. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies for Cardiovascular Disease (2005), Elsevier, St. Louis, MO 168-181
269. Lad V. An introduction to Ayurveda. Altern Ther 1 (1995) 57
270. Sharma H., Chandola H.M., Singh G., et al. Utilization of ayurveda in health care: an approach for prevention, health promotion, and treatment of disease. Part 2-Ayurveda in primary health care. J Altern Complement Med 13 10 (2007) 1135-1150
271. Hole L.C.N. Heart Qi and the heart of healing: Qigong for the prevention and treatment of cardiac diseases. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies for Cardiovascular Disease (2005), Elsevier, St. Louis, MO 182-203
272. Pippa L., Manzoli L., Corti I., et al. Functional capacity after traditional Chinese Medicine (Qi Gong) training in patients with chronic atrial fibrillation: a randomized controlled trial. Prev Cardiol 10 (2007) 22-25
273. Hui P.N., Wan M., Chan W.K., et al. An evaluation of two behavioral rehabilitation programs, qigong versus progressive relaxation, in improving the quality of life in cardiac patients. J Altern Complement Med 12 4 (2006) 351-353
274. Nauman E. Native American medicine and cardiovascular disease. Cardiol Rev 15 (2007) 35-41
275. Ai Gvhdi Waya. Native American healing for the heart. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies for Cardiovascular Disease (2005), Elsevier, St. Louis, MO 220-231
276. Whitmont R.D., and Mamtani R. Homeopathy with a special focus on treatment of cardiovascular disease. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies in Cardiovascular Disease (2005), Elsevier, St. Louis, MO 232-247
277. Shang A., Huwiler-Muntener K., Nartey L., et al. Are the clinical effects of homoeopathy placebo effects?. Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet 366 9487 (2005) 726-732
278. Goldacre B. Benefits and risks of homeopathy. Lancet 370 9600 (2007) 1672-1673
279. Prasad R. Homeopathy booming in India. Lancet 370 9600 (2007) 1679-1680
280. DiGiovanna E.L., Marinke D.J., and Dowling D.J. Introduction to osteopathic medicine. In: DiGiovanna E.L., and Schiowitz S. (Eds). An Osteopathic Approach to Diagnosis and Treatment. 2nd ed. (1997), Lippincott-Raven, New York, NY 2-13
281. Spiegel A.J., and Capobianco J.D. Osteopathic manipulative medicine in the treatment of hypertension. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies in Cardiovascular Disease (2005), Elsevier, St. Louis, MO 248-258
282. Pomeranz B. Scientific basis of acupuncture. In: Stux G., and Pomeranz B. (Eds). Acupuncture Textbook and Atlas (1987), Springer-Verlag, Berlin
283. Ulett G.A., Han J., and Han S. Traditional and evidence-based acupuncture: history, mechanism, and present status. South Med J 91 (1998) 1115-1120
284. Ernst E. Acupuncture: What does the most reliable evidence tell us?. J Pain Symptom Manage (2008) September 11, (epub ahead of print).
285. World Health Organization. A proposed standard international acupuncture nomenclature: report of WHO scientific group (1991), World Health Organization, Geneva
286. Weintraub M.I., Mamtani R., and Micozzi M.S. Complementary and Integrative Medicine in Pain Management (2008), Springer Publishing Co, New York, NY
287. Altman S. Techniques and instrumentation. Probl Vet Med 4 1 (1992) 66-87
288. Schlager A., Offer T., and Baldissera I. Laser stimulation of acupuncture point P6 reduces postoperative vomiting in children undergoing strabismus surgery. Br J Anaesthesia 81 (1998) 529-532
289. In: Weintraub M. (Ed). Alternative and Complementary Treatment in Neurologic Illness (2001), Churchill, New York, NY
290. Longhurst J.C. Central and peripheral neural mechanisms of acupuncture in myocardial ischemia. Intl Congress Series 1238 (2002) 79-87 (9)
291. Mamtani R., and Frishman W.H. Acupuncture in cardiovascular diseases. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies in Cardiovascular Disease (2005), Elsevier, St. Louis, MO 260-273
292. Williams T., Mueller K., and Cornwall M.W. Effect of acupuncture-point stimulation on diastolic blood pressure in hypertensive patients: a preliminary study. Phys Ther 71 (1991) 523-529
293. Richter A., Herlitz J., and Hjalmarson A. Effect of acupuncture in patients with angina pectoris. Eur Heart J 12 (1991) 175-178
294. Kurono Y., Egawa M., Yano T., et al. The effect of acupuncture on the coronary arteries as evaluated by coronary angiography: a preliminary report. Am J Chin Med 30 (2002) 387-396
295. NIH Consensus Development Conference Statement Online 1997. Acupuncture. http://odp.od.nih.gov/consensus/cons/107/107_statement.html Accessed February 10, 2004.
296. Longhurst J.C. Acupuncture's beneficial effects on the cardiovascular system. Prev Cardiol 1 (1998) 21-33
297. Calenda E., and Fleck S. Therapeutic massage and Asian bodywork. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies in Cardiovascular Disease (2005), Elsevier, St. Louis, MO 369-383
298. Song L.Z.Y.X., Schwartz G.E.R., and Russek L.G.S. Heart-focused attention and heart-brain synchronization: energetic and physiological mechanisms. Altern Ther 4 5 (1998) 44-62
299. Tiller W.A., McCraty R., and Atkinson M. Cardiac coherence: a new noninvasive measure of autonomic nervous system order. Altern Ther Health Med 2 1 (1996) 52-65
300. Spence J.E., and Olson M.A. Quantitative research on therapeutic touch: an integrated review of the literature 1985-1995. Scand J Caring Sci 11 (1997) 183-190
301. Heidt P. Effect of therapeutic touch on anxiety level of hospitalized patients. Nurs Res 30 (1980) 32-37
302. Olney C.M. The effect of therapeutic back massage in hypertensive patients: a preliminary study. Biol Res Nurs 7 2 (2005) 98-105
303. McNamara M.E., Burnham D.C., Smith C., et al. The effects of back massage before diagnostic cardiac catheterization. Altern Ther Health Med 9 (2003) 50-57
304. Delaney J.P., Leong K.S., Watkins A., and Brodie D. The short-term effects of myofascial trigger point massage therapy on cardiac autonomic tone in healthy subjects. J Adv Nurs 37 (2002) 364-371
305. Bisson D.A. Reflexology. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies in Cardiovascular Disease (2005), Elsevier, St. Louis, MO 331-341
306. Weintraub M.I., and Frishman W.H. Magnetic biostimulation: energy therapy. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies in Cardiovascular Disease (2005), Elsevier, St. Louis, MO 384-389
307. Weintraub M.I. Magnetotherapy: historical background with a stimulating future. Crit Rev Phys Rehab Med 16 (2004) 95-108
308. Keast M., and Adamo K. The Finnish sauna bath and its use in patients with cardiovascular disease. J Cardiopulmon Rehabil 20 (2000) 225-230
309. Hannuksela M., and Ellahham S. Benefits and risks of sauna bathing. Am J Med 110 (2001) 118-126
310. Hasan J., Karvonen M.J., and Piironen P. Special Review. Part I. Physiological effects of extreme heat as studied in the Finnish "sauna" bath. Am J Phys Med 45 (1966) 296-314
311. Hasan J., Karvonen M.J., and Piironen P. Special review. Part II. Physiological effects of extreme heat as studied in the Finnish "sauna" bath. Am J Phys Med 46 (1967) 1226-1246
312. Leppaluoto J., Tuominen M., Vaananen A., et al. Some cardiovascular and metabolic effects of repeated sauna bathing. Acta Physiol Scand 128 (1986) 77-81
313. Nguyen Y., Naseer N., and Frishman W.H. Sauna as a therapeutic option for cardiovascular disease. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies in Cardiovascular Disease (2005), Elsevier, St. Louis, MO 342-349
314. Mussivand T., Alshaer H., Haddad H., et al. Thermal therapy: a viable adjunct in the treatment of heart failure?. Congest Heart Fail 14 4 (2008) 180-186
315. Blum N., and Blum A. Beneficial effects of sauna bathing for heart failure patients. Exp Clin Cardol 12 1 (2007) 29-32
316. Diagnostic and therapeutic technology assessment: chelation therapy. JAMA 250 (1983) 672
317. Olszewer E., and Carter J.P. EDTA chelation therapy: a retrospective study of 2870 patients. J Adv Med 2 (1989) 197-211
318. Clarke N.E., Clarke C.N., and Mosher R.F. The "in vivo" dissolution of metastatic calcium: an approach to atherosclerosis. Am J Med Sci 229 (1955) 142-149
319. Eisenberg D.M., Davis R.B., Ettner S.L., et al. Trends in alternative medicine use in the United States, 1990-1997; results of a follow-up national survey. JAMA 280 (1998) 1569-1575
320. Chappell L.T., and Stahl J.P. The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med 6 (1993) 139-160
321. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina. A report of the American College of Cardiology/American Heart Association Trask Force on Practice Guidelines. J Am Coll Cardiol 33:2092-190 (published erratum 1999;34:314).
322. Cranton E.M. (1989), American College of Advancement in Medicine, Laguna Hills
323. Frishman W.H., Retter A., Misailidis J., et al. Innovative pharmacologic approaches to the treatment of myocardial ischemia. In: Frishman W.H., Sonnenblick E.H., and Sica D.A. (Eds). Cardiovascular Pharmacotherapeutics. 2nd ed. (2003), McGraw Hill, New York, NY 655-690
324. Frishman W.H., and Wolff A.I. Chelation therapy. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies in Cardiovascular Disease (2005), Elsevier, St. Louis, MO 288-299
325. Chappell L.T. Should EDTA chelation therapy be used instead of long-term clopidogrel plus aspirin to treat patients at risk from drug-eluting stents?. Altern Med Rev 12 2 (2007) 152-158
326. Mitka M. Chelation therapy trials halted (medical news & perspectives). JAMA 300 (2008) 2236
327. Wolff A.I., and Frishman W.H. Animal-assisted therapy and cardiovascular disease. In: Frishman W.H., Weintraub M.I., and Micozzi M. (Eds). Complementary and Integrative Therapies for Cardiovascular Disease (2005), Elsevier, St. Louis, MO 362-368
328. Tyberg A., and Frishman W.H. Animal-assisted therapy. In: Weintraub M.I., Mamtani R., and Micozzi M.S. (Eds). Complementary and Integrative Medicine in Pain Management (2008), Springer Publishing Co, New York, NY 115-123
329. Voith V. Attachment of people to companion animals. Vet Clin North Am Small Anim Pract 15 (1985) 289-5.
330. Marx M.B., Stallones T.F., Garrity J.R., et al. Demographics of pet ownership among US adults 21-64 years of age. Anthrozoos 2 1 (1988) 33-37
331. Francis G.M. Loneliness: measuring the abstract. Intl J Nurs Studies 13 (1976) 153-160
332. Delta Society. Standard of practice for animal assisted activities and therapy (1996), Delta Society, Renton, WA
333. Bueno E.A., Mamtani R., and Frishman W.H. Alternative approaches to the medical management of angina pectoris. Acupuncture, electrical nerve stimulation, and spinal cord stimulation. Heart Dis 3 (2001) 236-241
334. Kim M.C., Kini K., and Sharma S.K. Refractory angina pectoris. Mechanism and therapeutic options. J Am Coll Cardiol 39 (2002) 923-934
335. Eliasson T., Augustinsson L.-E., and Mannheimer C. Spinal cord stimulation in severe angina pectoris-presentation of current studies, indications and clinical experience. Pain 65 (1996) 169-179
336. Ansari S., Chaudhri K., and Moutaery K. Neurostimulation for refractory angina pectoris. Acta Neurochir Suppl 97 Pt. 1 (2007) 283-288
337. Marshall D.A., Walizer E., and Vernalis M.N. Optimal healing environments for chronic cardiovascular disease. J Alt Comp Med 10 suppl 1 (2004) S147-S155